Endomag develops wireless breast surgery localisation and lymphatic tracing solutions. Credit: ORION PRODUCTION / Shutterstock.

Hologic has closed the acquisition of UK-based breast cancer surgery technologies developer Endomagnetics (Endomag) for approximately $310m.

The deal between the parties was signed in April 2024.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Endomag is engaged in developing technologies for breast surgery, including the Magseed marker, Magtrace lymphatic tracing injectable, and the Sentimag platform.

Hologic breast and skeletal health solutions president Erik Anderson said: “We are thrilled to complete the acquisition of Endomag and are looking forward to working with our new colleagues to increase access to their innovative technologies, which complement and diversify our expanding interventional breast health portfolio.

“With our shared commitment to advancing women’s health globally, we are excited to improve outcomes for patients and, together with our customers, redefine the standard of care for breast cancer intervention.”

With the acquisition, Hologic added Endomag’s wireless breast surgery localisation and lymphatic tracing solutions to its breast surgery portfolio.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

This provides breast surgeons and radiologists with an expanded range of options and improve user experience.

Endomag CEO Eric Mayes said: “We are so proud of the company we built and the practice-changing breast surgery technologies that we developed following years of relentless research, innovation and deep engagement with clinicians.

“As we embark on this new journey with Hologic, I am filled with optimism about the opportunities for our team, our forthcoming innovations and our ability to impact even more women around the world.”

For the 2023 calendar year, the company posted revenues of $35m.

The acquisition is projected to have a slight dilutive effect on Hologic’s non-GAAP earnings per share for the fiscal year 2024.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
SC MEDICA’s minimally invasive, radiation free spinal facet fixation system, FFX® is transforming spinal pain management and improving outcomes for surgeons and patients alike. Learn how SC MEDICA’s award-winning technology is redefining standards in facet joint pain treatment.

Discover the Impact